Anemia
Conference Coverage
Sickle cell crises curtailed with experimental cellular adhesion inhibitor
Major finding: The mean time to resolution of vaso-occlusive crisis in patients with sickle cell disease was 103 hours for patients treated with...
News
Drug gets orphan designation for MDS
The drug, CPI-613, targets metabolic changes that are thought to occur in many cancer cells. It has demonstrated activity and tolerability in a...
Clinical Review
Autoimmune Hemolytic Anemia
News
FDA approves plasma product
The FDA has approved a pooled plasma blood product (Octaplas) that can be used to replace coagulation factors in patients with certain medical...
News
Despite efficacy, most patients discontinued therapy
In a multicenter trial, deferasirox reduced serum ferritin and labile plasma iron (LPI) in transfusion-dependent patients with myelodysplastic...
News
Drug for aHUS effective but expensive
AMSTERDAM—Eculizumab elicits “phenomenal” results in atypical hemolytic uremic syndrome (aHUS), according to two presentations given at the 17th...
Conference Coverage
Hematologists, Hospitalists Differ in Care of Sickle Cell Patients
Major Finding: Compared with sickle cell patients cared for by a hospitalist, those cared for by a hematologist had more hours on a patient-...
Conference Coverage
New Data Support Continuing Hydroxyurea for Pediatric Sickle Cell
Major Finding: Compared with children not taking hydroxyurea, those who continue to take hydroxyurea have statistically lower rates of pain crises...
News
FDA approves deferiprone to treat iron overload
The FDA has approved deferiprone (Ferriprox) to treat iron overload in thalassemia patients who had an inadequate response to prior chelation...
News
FDA Approves Deferiprone for Transfusional Iron Overload
News
Team corrects SCD mutation with iPS cells
Using induced pluripotent stem (iPS) cells, researchers have corrected the genetic alteration that causes sickle cell disease (SCD). The...